Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 76

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 76
---
 named executive officer other than himself. The compensation committee considers the information provided by the Chief Executive Officer, together with other information available to the compensation committee such as peer group and other data provided by Aon, and determines the compensation for each named executive officer. Role of Compensation Consultants The compensation committee engaged Aon to assist with the committee’s 2024 compensation review, analysis and actions. Aon’s services generally included: • identifying an updated market framework (including a peer group of companies) to use as a reference point; • gathering data on our executive officer cash and equity compensation levels relative to competitive market practices; and • developing a market-based framework for potential changes to our compensation program for the compensation committee’s review and input. After review and consultation with Aon, our compensation committee determined that Aon is independent, and that there is no conflict of interest resulting from retaining Aon during fiscal year 2024. In reaching these conclusions, our compensation committee considered the factors set forth in the SEC rules and the Nasdaq listing standards. Other than the services provided to our compensation committee, including consulting services with respect to director compensation matters, Aon did not perform any other work for us in 2024 that exceeded $120,000.

<div align='center'>50</div>

II. 2024 Named Executi ve Officer Compensation Detailed Analysis of 2024 Exe cutive Compensation Program Competitive Market Review for 2024 In determining the 2024 base salaries, cash bonus opportunities and equity grants for our named executive officers, our compensation committee used competitive market data based on the following peer group that was developed with input from Aon, and approved by the compensation committee, in September 2023:

| PEER GROUP                                                                                                                                                                                                               |                                                                                                                                                                                                                                          |
|      ACADIA Pharmaceuticals, Inc.      Alkermes     Alnylam Pharmaceuticals Inc.      BioMarin Pharmaceutical Inc.      Blueprint Medicines     Exelixis, Inc.      Halozyme Therapeutics, Inc.     Incyte Corp. |      Ionis Pharmaceuticals Inc.     Jazz Pharmaceuticals plc      Neurocrine Biosciences, Inc.      PTC Therapeutics      Repligen Corporation     Sage Therapeutics     Ultragenyx Pharmaceutical Inc.      United Therapeutics |

This peer group (the "2024 Peer Group") was selected after consideration of the following criteria: industry sector, stage of